Urogen Pharma Ltd URGN

$29.79 -0.08 (-0.27%)

Valuation

Market cap
1,465,064,000
Revenue TTM
$109,790,000
Net income TTM
$-153,490,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-139.80%
Debt to equity
-1.51

Trading

Volume
1,144,200
Avg volume
1,161,782
Day's range
$28.15 – $30.17
Shares out
49,048,000
Stochastic %K
95%
Beta
1.68
Analysts
Strong Buy
Price target
$56.89

Price

Company profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a su...

Show more

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
646 768 9780
Website
https://www.urogen.com
Address
400 Alexander Park Drive, 4th Floor, Princeton, United States

Latest news

Stocktwits

lonelywarrior Nov 18, 3:58 PM
$URGN Taking a little breather here on low volume before moving on higher.
0 replies
topstockalerts Nov 17, 9:37 PM
$URGN definitely worth keeping an eye on
0 replies
24DV4NC3D Nov 17, 9:00 PM
$URGN ⚡️WHAT DID I SAY?!⚡️ 🃏💥🃏💥🃏💥🃏💥🃏 STOCK OF THE DAY #4 >>>>> 🎯🎯🎯 <<<< >>>>> LISTEN! <<<<<<
0 replies
lonelywarrior Nov 17, 8:06 PM
$XBI - $URGN, $TVTX, $RARE holding nice today because fundamentals, revenue and FDA-approved products matter.
0 replies
Grinding10 Nov 17, 5:04 PM
$CGON $URGN that’s funny geniuses told me the approval was priced in at $26😃
0 replies
lonelywarrior Nov 17, 3:43 PM
$URGN This is the moment when $CGON is downgraded though price target increased and the realization comes that $URGN is in much stronger position business-wise with FDA-approved products generating revenue while $CGON results are already priced-in and are unlikely to materialize as the actual FDA approval until 2028.
1 replies
GSP Nov 17, 12:16 PM 0 replies
GSP Nov 16, 10:00 PM
My Day Trading Watch List Video for November 17th in About 3 Minutes: $SPY $SAIQ $URGN $CLRO $TSN .
0 replies